T-Guard
- Generic Name
- T-Guard
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Xenikos
- Target Recruit Count
- 12
- Registration Number
- NCT04934670
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Xenikos
- Target Recruit Count
- 3
- Registration Number
- NCT04128319
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸University of Kansas, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath